Skip to main content

Table 1 Group characteristics from Gelman et al., 2012[70]

From: Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer’s disease

Group (N) HIV status Neurocognitive Impairment (GCR) HIVE CPE* Age (years) PMI (hours)
A (6) Negative No (NA) NA NA 50 ± 10 19 ± 5.1
B (4) Positive No (2.8 ± 1.3) No 2.1 ± 0.9 50 ± 6.5 11 ± 8.1
C (7) Positive Yes (7.1 ± 0.7) No 1.3 ± 2 44 ± 9.8 7.2 ± 2.1
D (4) Positive Yes (8.3 ± 1.7) Yes 1.8 ± 0.3 44 ± 10 11 ± 4.8
  1. * Note that this grouping schema was used only on one analysis in Study1.
  2. ** CNS Penetration Effectiveness. Higher values indicate greater penetration of antiretroviral medications into brain.